These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11369655)

  • 1. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.
    Stirewalt DL; Kopecky KJ; Meshinchi S; Appelbaum FR; Slovak ML; Willman CL; Radich JP
    Blood; 2001 Jun; 97(11):3589-95. PubMed ID: 11369655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
    Kiyoi H; Naoe T; Nakano Y; Yokota S; Minami S; Miyawaki S; Asou N; Kuriyama K; Jinnai I; Shimazaki C; Akiyama H; Saito K; Oh H; Motoji T; Omoto E; Saito H; Ohno R; Ueda R
    Blood; 1999 May; 93(9):3074-80. PubMed ID: 10216104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.
    Kottaridis PD; Gale RE; Langabeer SE; Frew ME; Bowen DT; Linch DC
    Blood; 2002 Oct; 100(7):2393-8. PubMed ID: 12239147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
    Fröhling S; Schlenk RF; Breitruck J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K;
    Blood; 2002 Dec; 100(13):4372-80. PubMed ID: 12393388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of p51, p53, FLT3 and N-ras genes and their prognostic value in relapsed acute myeloid leukemia.
    Nakamura H; Inokuchi K; Yamaguchi H; Dan K
    J Nippon Med Sch; 2004 Aug; 71(4):270-8. PubMed ID: 15329487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
    Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
    Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
    Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
    Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
    Stirewalt DL; Meshinchi S; Kussick SJ; Sheets KM; Pogosova-Agadjanyan E; Willman CL; Radich JP
    Br J Haematol; 2004 Feb; 124(4):481-4. PubMed ID: 14984498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.
    Bianchini M; Ottaviani E; Grafone T; Giannini B; Soverini S; Terragna C; Amabile M; Piccaluga PP; Malagola M; Rondoni M; Bosi C; Baccarani M; Martinelli G
    Clin Chem; 2003 Oct; 49(10):1642-50. PubMed ID: 14500589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia.
    Ozeki K; Kiyoi H; Hirose Y; Iwai M; Ninomiya M; Kodera Y; Miyawaki S; Kuriyama K; Shimazaki C; Akiyama H; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Ueda R; Ohno R; Emi N; Naoe T
    Blood; 2004 Mar; 103(5):1901-8. PubMed ID: 14604973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
    Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene.
    Nakano Y; Kiyoi H; Miyawaki S; Asou N; Ohno R; Saito H; Naoe T
    Br J Haematol; 1999 Mar; 104(4):659-64. PubMed ID: 10192423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples.
    Shih LY; Huang CF; Wu JH; Wang PN; Lin TL; Dunn P; Chou MC; Kuo MC; Tang CC
    Clin Cancer Res; 2004 Feb; 10(4):1326-32. PubMed ID: 14977832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.
    Stirewalt DL; Willman CL; Radich JP
    Leuk Res; 2001 Dec; 25(12):1085-8. PubMed ID: 11684280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
    Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.